about
Single-nucleotide polymorphisms: a perspective of cardiovascular preventionPharmacogenomics and cardiovascular diseasePharmacogenetic Foundations of Therapeutic Efficacy and Adverse Events of Statins.ApoE polymorphism may determine low-density lipoprotein cholesterol level in association with obesity and metabolic syndrome in postmenopausal Korean womenGenetic testing for early detection of individuals at risk of coronary heart disease and monitoring response to therapy: challenges and promisesApolipoprotein E mRNA expression in mononuclear cells from normolipidemic and hypercholesterolemic individuals treated with atorvastatin.Impact of common genetic variation on response to simvastatin therapy among 18 705 participants in the Heart Protection StudyClinical delivery of pharmacogenetic testing services: a proposed partnership between genetic counselors and pharmacists.Atorvastatin Therapy Modulates Telomerase Activity in Patients Free of Atherosclerotic Cardiovascular DiseasesThe ABCG2 transporter and its relations with the pharmacokinetics, drug interaction and lipid-lowering effects of statins.Effect of apolipoprotein E polymorphism on statin-induced decreases in plasma lipids and cardiovascular events.A systematic review on pharmacogenetics in cardiovascular disease: is it ready for clinical application?Pharmacogenetics of statins: achievements, whole-genome analyses and future perspectives.Pharmacogenomics of adverse drug reactions: implementing personalized medicine.Expanding role of pharmacogenomics in the management of cardiovascular disorders.Genetics and personalized medicine--a role in statin therapy?Polymorphisms and haplotypes in TLR9 and MYD88 are associated with the development of Hodgkin's lymphoma: a candidate-gene association study.Ten-year progress of coronary artery lesions prior to Behçet disease diagnosis: A case report and care-compliant article.
P2860
Q26776025-256E1AF3-A050-4B4F-B08D-991D101350A9Q26997380-033B5C51-F6DD-455D-87BB-C5A3FB2A17B9Q34680467-C0A166C4-712F-4DA0-AFE8-01ED3A12B581Q35003338-D6D0389B-4478-46A4-89ED-7E46AB00335DQ35190833-810A2AE1-BFF0-4058-91F1-15449BA2EDD2Q35639536-3D400585-7A68-4E3F-AE03-EBCCDA7EBBF8Q36730132-981B7EA9-1C85-459C-80B0-B9D4CE1BF8A6Q37065155-3645733F-88A7-487E-A596-05D79333619AQ37298151-EC5DC8ED-9312-45D1-8C99-BEAA1C3E5242Q37810986-E072B9C7-0CB0-484D-BCD3-7070F7115D23Q37873935-AE0F7825-A469-462D-BD90-3DEA16B5F913Q37908891-C4C35C9B-CD62-49EE-8333-5813415C0920Q38010751-19832159-40BB-429B-9AA0-C652511E4386Q38036150-6919375A-32A0-4974-83C9-86CF872DF722Q38098452-2485F902-0AE8-44E4-A850-34DE99CB00F1Q38167710-1DDA5C4D-2052-4842-B2A7-44FB327E7228Q45888335-65EFD7F7-26D2-4748-B514-F81FDDFD3983Q49815791-FBD15912-97A2-4528-A98E-EF8041D46B5D
P2860
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
APOE gene polymorphisms and response to statin therapy.
@en
APOE gene polymorphisms and response to statin therapy.
@nl
type
label
APOE gene polymorphisms and response to statin therapy.
@en
APOE gene polymorphisms and response to statin therapy.
@nl
prefLabel
APOE gene polymorphisms and response to statin therapy.
@en
APOE gene polymorphisms and response to statin therapy.
@nl
P2093
P2860
P356
P1476
APOE gene polymorphisms and response to statin therapy.
@en
P2093
P2860
P2888
P304
P356
10.1038/TPJ.2009.25
P577
2009-06-16T00:00:00Z
P5875
P6179
1031073561